Patents by Inventor Andrew M. Blumenfeld

Andrew M. Blumenfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE
    Publication number: 20240050540
    Abstract: Disclosed herein are compositions and methods for use in treating headache.
    Type: Application
    Filed: October 23, 2023
    Publication date: February 15, 2024
    Inventors: Gregory F. Brooks, Andrew M. Blumenfeld
  • Neurotoxin compositions for use in treating headache
    Patent number: 11826405
    Abstract: Disclosed herein are compositions and methods for use in treating headache.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: November 28, 2023
    Assignee: Aeon Biopharma, Inc.
    Inventors: Gregory F. Brooks, Andrew M. Blumenfeld
  • SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS
    Publication number: 20230263869
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: November 23, 2022
    Publication date: August 24, 2023
    Inventor: Andrew M. Blumenfeld
  • CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC AND NEUROLOGICAL DISORDERS
    Publication number: 20230158128
    Abstract: Methods for treating neurological or neuropsychiatric disorder and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Inventors: Mitchell F. Brin, Andrew M. Blumenfeld
  • COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
    Publication number: 20230105611
    Abstract: Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.
    Type: Application
    Filed: May 2, 2022
    Publication date: April 6, 2023
    Inventors: Andrew M. Blumenfeld, Mitchel F. Brid
  • Treatment of psychological trauma
    Patent number: 11077174
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: August 3, 2021
    Assignee: Allergan, Inc.
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES FOR THE TREATMENT OF CORTICAL SPREADING DEPRESSION ASSOCIATED DISORDERS
    Publication number: 20210128724
    Abstract: Methods for the treatment and prevention of diseases and disorders associated with cortical spreading depression by administering a CGRP antagonist, a Clostridial derivative or combination thereof are described.
    Type: Application
    Filed: July 6, 2020
    Publication date: May 6, 2021
    Inventors: Rami Burstein, Agustin Melo Carrillo, Mitchell F. Brin, Andrew M. Blumenfeld
  • CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
    Publication number: 20210121541
    Abstract: Methods for treating neurological or neuropsychiatric disorder and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.
    Type: Application
    Filed: July 6, 2020
    Publication date: April 29, 2021
    Inventors: Mitchell F. Brin, Andrew M. Blumenfeld
  • SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS
    Publication number: 20210121543
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 29, 2021
    Inventor: Andrew M. Blumenfeld
  • NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE
    Publication number: 20210060144
    Abstract: Disclosed herein are compositions and methods for use in treating Migraine, for example Episodic or Chronic Migraine, including methods with reduced side effects and comparable or improved efficacy as compared to methods known in the art.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 4, 2021
    Inventors: Gregory F. Brooks, Andrew M. Blumenfeld
  • Suture line administration technique using botulinum toxins
    Patent number: 10874722
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: December 29, 2020
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO
    Publication number: 20200383983
    Abstract: The application provides methods for treating, preventing, alleviating or reducing the frequency of occurrence of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo in patients by the administration of calcitonin gene-related peptide (CGRP-antagonists). The CGRP-antagonists can be selected from ubrogepant or atogepant, or a pharmaceutically acceptable salt, ester or prodrug thereof. Anti-CGRP antibodies, such galcanezumab, fremanezumab, eptinezumab, and erenumab can also be used.
    Type: Application
    Filed: April 17, 2020
    Publication date: December 10, 2020
    Inventors: Mitchell F. Brin, Andrew M. Blumenfeld
  • INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS
    Publication number: 20200360492
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Injection paradigm for administration of botulinum toxins
    Patent number: 10729751
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 4, 2020
    Assignee: Allergan, Inc.
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • TREATMENT OF PSYCHOLOGICAL TRAUMA
    Publication number: 20200061164
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 27, 2020
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
    Publication number: 20200030415
    Abstract: Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.
    Type: Application
    Filed: July 5, 2019
    Publication date: January 30, 2020
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin
  • Treatment of psychological trauma
    Patent number: 10456455
    Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 29, 2019
    Assignee: Allergan, Inc.
    Inventors: Kenton B. Abel, Andrew M. Blumenfeld
  • Suture Line Administration Technique Using Botulinum Toxins
    Publication number: 20190240299
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Application
    Filed: March 4, 2019
    Publication date: August 8, 2019
    Inventor: Andrew M. Blumenfeld
  • Suture line administration technique using botulinum toxins
    Patent number: 10220079
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: March 5, 2019
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS
    Publication number: 20190060423
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Andrew M. Blumenfeld, Mitchell F. Brin